Description:
PF-1355 is a selective, mechanism-based inhibitor of myeloperoxidase (MPO) (IC50 = 1.5 μM in LPS-stimulated human whole blood) with excellent selectivity for MPO without disrupting a panel of 50 receptors, enzymes, ion channels and transporters, including thyroid peroxidase. PF-1355 was used to test the hypothesis that MPO activity is a critical mediator of disease activity in immune complex vasculitis mouse models, and to support the confidence in rationale for this mechanism as a therapeutic approach to treat related human condition such as alleviating tissue injury caused by Goodpasture syndrome and pulmonary vasculitis induced by immune complexes.
- Molecular Weight: 321.35
- Molecular Formula: C14H15N3O4S
Canonical SMILES:
COC1=CC(=C(C=C1)OC)C2=CC(=O)NC(=S)N2CC(=O)N
InChI:
InChI=1S/C14H15N3O4S/c1-20-8-3-4-11(21-2)9(5-8)10-6-13(19)16-14(22)17(10)7-12(15)18/h3-6H,7H2,1-2H3,(H2,15,18)(H,16,19,22)
InChIKey: LJBUZOGABRDGBR-UHFFFAOYSA-N- Solubility: Soluble to 20 mM in DMSO
- Appearance: Solid powder
- Storage: Store in a cool and dry place and at 0 - 4°C for short term (days to weeks) or -42°C for long term (months to years).
Synonyms:
2-(6-(2,5-dimethoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide;PF-06281355; PF 06281355; PF06281355; PF-1355; PF 1355; PF1355.
More details are to be found on supplier website
